Glycosmis ovoidea
Glycosmis ovoidea · Accepted scientific name
Scientific literature: Very Sparse (0 studies) · ★☆☆☆☆
Glycosmis ovoidea is a medicinal plant that has garnered significant attention within the field of ethnopharmacology. Researchers are increasingly investigating its bioactive compounds to determine their potential efficacy against various forms of cancer. Preliminary studies suggest that certain phytochemicals within the plant may possess antiproliferative properties capable of inhibiting tumor growth. Understanding the molecular mechanisms of these extracts is crucial for developing targeted therapeutic strategies. Consequently, this species represents a promising natural resource in the ongoing search for novel anticancer agents.
- Synonyms
- Glycosmis Singuliflora Var. Glabra · Glycosmis Craibii Var. Glabra
- Common names
- Not available
- Family
- Rutaceae
- Distribution
- Asia-Tropical
- Plant Parts
- Not available
Classification
Synonyms
Glycosmis ovoidea is a botanical species that is frequently identified through various taxonomic synonyms in scientific literature. For instance, it is often referred to in older studies as Glycosmis craibii var. glabra. Additionally, the plant is recognized under the alternative name Glycosmis singuliflora var. glabra. These overlapping classifications can sometimes cause confusion for researchers navigating diverse botanical databases. Understanding these nomenclatural relationships is essential for ensuring accurate identification and consistent communication within the field of botany.
Sources: The World Checklist of Vascular Plants (WCVP)
Taxonomy
Glycosmis ovoidea is a distinctive member of the kingdom Plantae. Within this vast biological realm, the species is classified under the class Equisetopsida. It belongs to the order Sapindales, which helps define its evolutionary lineage. Furthermore, the plant is nested within the family Rutaceae, showcasing its botanical connections. Ultimately, its taxonomic identity is anchored within the specific genus Glycosmis.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Sapindales |
| Family | Rutaceae |
| Genus | Glycosmis |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Glycosmis ovoidea exhibits a widespread distribution across various regions of the Asian continent. In temperate climates, the species can be found specifically within China and the Hainan province. Its presence extends significantly into tropical Asia, where it thrives throughout the Indo-China peninsula. This includes established populations in Cambodia, Myanmar, and Thailand. Additionally, the plant is commonly documented growing within the tropical landscapes of Vietnam.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Biological Activities
Compounds
Glycosmis ovoidea is a plant species from the Rutaceae family that has been studied for its potential medicinal properties. During research conducted in Vietnam, scientists isolated several unique coumarins from this tropical plant. One significant compound identified during this process is kimcuongin. While kimcuongin itself was found to be non-cytotoxic against certain cancer cell lines, it plays a crucial role in enhancing the efficacy of other substances. Specifically, it can significantly potentiate the cytotoxicity of certain flavonoids against breast cancer cells by inhibiting key molecular targets.
Conditions
Glycosmis ovoidea contains bioactive compounds that demonstrate significant potential in treating various forms of cancer. Specifically, the plant's derived flavone PMF effectively treats MCF-7 breast cancer cells by inducing apoptosis through the intrinsic pathway. This same substance also treats MCF-7 cell migration, which may be linked to the downregulation of NF-κB p65. Furthermore, the extracts show the ability to treat MCF-10A cells by inhibiting their growth. Finally, the antiproliferative effects of these constituents extend to the treatment of MDA-MB-231 cells.